1. Home
  2. NABL vs PCRX Comparison

NABL vs PCRX Comparison

Compare NABL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NABL
  • PCRX
  • Stock Information
  • Founded
  • NABL 2000
  • PCRX 2006
  • Country
  • NABL United States
  • PCRX United States
  • Employees
  • NABL N/A
  • PCRX N/A
  • Industry
  • NABL Computer Software: Prepackaged Software
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NABL Technology
  • PCRX Health Care
  • Exchange
  • NABL Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • NABL 1.2B
  • PCRX 1.2B
  • IPO Year
  • NABL N/A
  • PCRX 2011
  • Fundamental
  • Price
  • NABL $7.80
  • PCRX $26.00
  • Analyst Decision
  • NABL Buy
  • PCRX Buy
  • Analyst Count
  • NABL 4
  • PCRX 9
  • Target Price
  • NABL $9.38
  • PCRX $29.89
  • AVG Volume (30 Days)
  • NABL 1.4M
  • PCRX 891.6K
  • Earning Date
  • NABL 05-08-2025
  • PCRX 05-08-2025
  • Dividend Yield
  • NABL N/A
  • PCRX N/A
  • EPS Growth
  • NABL N/A
  • PCRX N/A
  • EPS
  • NABL 0.08
  • PCRX N/A
  • Revenue
  • NABL $470,595,000.00
  • PCRX $702,772,000.00
  • Revenue This Year
  • NABL $7.97
  • PCRX $8.63
  • Revenue Next Year
  • NABL $9.61
  • PCRX $11.66
  • P/E Ratio
  • NABL $97.14
  • PCRX N/A
  • Revenue Growth
  • NABL 7.98
  • PCRX 3.08
  • 52 Week Low
  • NABL $6.07
  • PCRX $11.16
  • 52 Week High
  • NABL $15.49
  • PCRX $31.64
  • Technical
  • Relative Strength Index (RSI)
  • NABL 54.79
  • PCRX 49.37
  • Support Level
  • NABL $7.77
  • PCRX $25.33
  • Resistance Level
  • NABL $7.99
  • PCRX $26.44
  • Average True Range (ATR)
  • NABL 0.19
  • PCRX 0.91
  • MACD
  • NABL -0.03
  • PCRX -0.03
  • Stochastic Oscillator
  • NABL 23.08
  • PCRX 61.96

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: